-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
[unable to retrieve full-text content]
The combination of dabrafenib and trametinib has shown activity in several BRAFV600E-mutated cancers. We aimed to assess the activity and safety of …
Published at Mon, 17 Aug 2020 22:30:00 +0000